Work

Sequencing the anti-EGFR-TKIs; route to the longest survival

Year: 2024

Type: article

Abstract: We read the article titled ‘Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC’ by Uehara et al.1 Thanks to the authors for broadening the understanding of treatment approaches in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer with real-life data. Nevertheless, we have some concerns to state.

Source: ESMO Real World Data and Digital Oncology

DOI: 10.1016/j.esmorw.2024.100074

Authors: H.G. Güzel, Y. İlhan, A.H. Önder

Institutions: Antalya Eğitim ve Araştırma Hastanesi, Antalya Şehi̇r Hastanesi̇

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,020